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I.  INTRODUCTION 
1.  Council  Directive  75/319/EEc(*)  provides,  in  Article 15,  that the 
Commission  shall  report  to the  Council  annually on  the operation of  the 
procedure  of  the  Committee  for  Proprietary Medicinal  Products  and  its 
effects on  the development  of  intra-Community  trade. 
This  Fourth  Report(**)  covers  in  particular the  Committee's  activities 
from  July  1981  to  September  1982. 
2.  The  Committee's  procedure,  which  permits  the  holder  of  a  marketing 
authorization to  send  an  application  for  marketing  authorization to 
at  Least  five other  Member  States  by  way  of the  Member  State  which 
granted the authorization,  is still in  reality an  exceptional  procedure 
when  compared  with  the  filing  of  separate  applications  in each  Member 
State. 
Nevertheless,  the  28  applications  received  in  five  years,  above  all 
since the  end  of  1980,  are  useful  pointers on  the  way  towards  the 
free  movement  of  medicinal  products. 
3.  Cooperation  within the  Committee  between  those  responsible  at  national 
level  for  marketing  authorizations  has  developed  further,  especially 
as  regards  the  exchange  of  information on  the side effects of 
medicines  (drug  monitoring).  The  increasing  part  played  by  the  Committee 
in  the  coordination of  national  decisions  on  marketing  authorizations, 
as  provided  for  in  Articles  12  and  14  of  Directive  75/319/EEC,  is the 
most  encouraging  aspect  of its current  operation. 
. I. 
(*)  OJ  No  L 147,  9.6.75 
(**)  The  file  references  of  the three  previous  reports  are  COM(79)59,  22.2.79; 
COM(80)149,  31.1.80;  and  COM(81)363,  13.7.81. - 3  -
4.  The  experience gained  within  the  Committee  makes  a  useful  contribution 
to the discussions  which  have  been  held  by  the  Council's  experts  since 
November  1981  on  the proposal(*)  for  the  amendment  of  Directives 
65/65/EEC,  75/318/EEC  and  75/319/EEC.  The  Commission  has  involved 
itself in these discussions  in  order  to ensure that the  new  procedure 
for  the  recognition of authorizations  that  is being  proposed  to  manu-
facturers  remains  attractive  and  is not  weighed  down  with  measures 
which  are  likely to  be  no  more  successful  than the present  procedurea 
The  Committee's  experience  will  in  part  be  beneficial to the activities 
of the  future  Committee  for  Veterinary  Medicinal  Products  set  up  by 
Council  Directive  81/851/EEc<**)  which,  together  with  Directive 
81/852/EEc<**',  will  henceforth  govern  marketing  authorization  for 
veterinary medicines. 
5.  The  development  of  intra-Community  trade  in  medicinal  products  between 
1975  and  1981  is  shown  in  Annex  I.  From  1981  onwards,  Greece  is 
included.  In  1981,  intra-Community  trade  continued to account  for  the 
greater  part  (70.5  %)  of the total  imports  by  Member  States.  The 
balance of trade  in  medicinal  products  between  the  Community  and 
non-member  countries  is still in  substantial  surplus. 
(*)  OJ  No  C 355,  31.12.80 
(**)  OJ  No  L 317,  6.11.81 
.1. 
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II.  FUNCTIONING  OF  THE  PROCEDURE  PROVIDED  FOR  IN  ARTICLES  9  TO  11  OF 
DIRECTIVE  75/319/EEC 
1.  General 
It  should  be  remembered  first of all that the procedure  provided  for 
in  Articles 9  to  11  of  Directive  75/319/EEC  is not  a  Community 
registration procedure  for  medicinal  products.  It  is a  special 
means  of  submitting  application dossiers  which  is  intended to  make 
it easier to obtain  marketing  authorization  in  five or  more  Member 
States,  on  the basis of  an  authorization obtained  in  one  Member  State 
in  accordance  with  the  criteria set  out  in the directives  relating  to 
proprietary medicinal  products.  During  the  period  for  examination of 
applications,  which  is  120  days  as  in  the  case of the  normal  national 
procedure  provided  for  in  Directive  65/65/EEC,  the  Member  States  can 
issue  reasoned  objections  on  which  the  Committee  has  to give its 
non-binding  opinion  within  60  days.  At  the  end  of this  Community 
consultation phase,  the  Member  States  concerned  reach  a  decision 
on  the  marketing  eutk~rization, applying  the  same  criteria as 
in  the  purely national  procedures  and  complying  with  Articles  30  to 
.  .  .  (  **)  l  .  .  36  of  the  EEC  Treaty  and  w1th  the  D1rect1ves  re  at1ng  to propr1etary 
medicinal  products. 
2.  Applications  filed  in  accordance  with  the  Committee's  procedure 
Since  the  second  half of  1980  the number  of  applications  has  been 
growing  steadily if a  little slowly.  Some  applications  concern  several 
different  presentations  (dosage  form  or  strength)  of the  same  active 
principle,  and  therefore,  strictly speaking,  several  proprietary 
medicinal  products. 
.I. 
(*)  OJ  No  22,  9.2.65 
<**)  Directives  65/65/EEC  and  75/319/EEC  cited above; 
Directive  75/318/EEC,  OJ  No  L 147,  9.6.75  (tests of medicinal  products>; 
Directive 78/25/EEC,  OJ  No  L 11,  14.1.78  (colouring  agents). - 5  -
1978  1979  1980  1981  1982  (9  months)  TOTAL  (Sept.  82) 
Number  of  2  2  7  7  10  28  applications 
Number  of 
proprietary 
medicinal  5  2  12  11  14  44 
products  (or 
presentations) 
These  28  applications  forwarded  to the  Committee  cover  179  national  appli-
cations  for  authorization,  which  is  an  indication that the geographical 
spread of  recent  applications  has  widened.  The  index  for  the number  of 
countries  per  application  has  risen  from  5.875  in  July  1981  to 6.4 
in  September  1982,  the  minimum  number  of  Member  States permitted 
under  the  procedure  being  five. 
As  a  rule the  firms,  in  agreement  with  the  Member  State  which  has 
notified the  Committee,  take  it  upon  themselves  to  send  the dossier 
to the  Member  States  which  the  application  concerns  and  to the 
secretariat of  the  Committee.  In  view  of the  considerable  size of 
some  of  the dossiers,  the  time  taken  for  filing  the application depends 
on  how  it  is  routed;  the  quickest  way  is  for  the  firm  itself to file 
the  application. 
The  secretariat  is  informed  by  telex or  telephone  by  the  countries 
receiving  the  applications,  in  order  that it may  fix  the date  when 
the  120-day  period  for  examination of the dossiers  is to start  as 
soon  as  they  have  arrived  in  all  the  countries  concerned. 
. I. • 
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The  28  applications  recorded  (September  1982)  show  that  a  gradual 
diversification  is taking  place  as  regards  the origin  and  destination 
of applications. 
~ut of  28 
applications  B  D  OK  F  GR  IRL  IT  LUX  NL  UK 
at  September  1982 
Number  of 
~pplications  4  3  5  5  0  0  0  0  0  11  filed  by  the 
country 
Number  of 
applications  23  17  18  12  5  16  21  26  25  13  made  to 
the  country 
Total = 
"participation  27  20  23  17  5  16  21  26  25  24 
index" 
Only  five  countries  have  forwarded  applications:  these are,  above  all, 
the  United  Kingdom,  followed  by  France,  Denmark,  Belgium  and  Germany. 
More  effort  should  perhaps  be  made  in the other  Member  States to  inform 
the manufacturing  companies  of the opportunities offered by  the 
Committee's  procedure. 
The  countries to  which  applications  are  made  are  chiefly those 
with  relatively  small  markets,  namely  Luxembourg,  the  Netherlands, 
Belgium  and  Denmark.  Firms  have  a  tendency  to file  separate  applications, 
for  example  in  the  United  Kingdom,  France  and  Germany,  before  making 
use  of the  Committee's  procedure  to  apply  in the other  Member  States. 
Moreover,  medicinal  products  are  often  registered in  the  United 
Kingdom  and  in  Ireland  simultaneously. 
The  total of the  two  figures  to  some  extent  provides  an  index  of the 
"participation" of each  Member  State  in  the  procedure,  both  as  an 
applicant  and  as  a  recipient.  This  "participation index"  is clearly 
very  similar  for  all  the  Member  States except  Greece,  which  has  only 
recently  joined. 
. I. Origin 
group 
Number 
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The  Committee's  procedure  takes  place prior to the granting  of  marketing 
authorizations,  and  in the applicants'  interest the names  of the  firms 
and  medicinal  products  concerned  are  therefore  not  made  public.  It  should 
be  noted,  however,  that  the  28  applications  are  more  or  Less  equally 
shared  between  major  multinationals  and  medium-sized  undertakings. 
It  is also  worth  taking  a  Look  at  the original  nationality of the 
undertakings  or  the groups  to  which  they  belong,  on  the basis  of the 
information available  and  on  the  understanding  that this  concept 
might  give  cause  for  discussion.  It goes  without  saying  that  the 
applicant  firms  are  all established within the territory of the 
Community. 
of  USA  DK  F  8  SWEDEN  UK  D  NL 
of 
applications  8  7  5  3  2  1  1  1 
Number  of  7  3  5  1  2  1  1  1  firms 
The  applications  cover  a  wide  variety of  product  types: 
- 4 non-steroid  anti-inflammatory  agents 
- 3 antibiotics 
- 3  analgesics 
- 3  antihypertensives 
- 1  anti-anginal  agent 
- 1 oral  contraceptive 
- 1  anaesthetic  solution 
- 1  anti-osteoclastic  (Paget's disease) 
- 1  potassium 
- 1  calcium 
- 1  antitussive  syrup 
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- 1 anti dyspeptic 
- 1  anti-smoking  drug 
- 1  anti-glaucoma  collyrium 
- 1 glucocorticoid-based nasal  spray 
- 1 powder  for  varicose  ulcers 
- 1 occlusive gel  for  surgical  use 
- 1  topical  solution  for  the treatment  of  herpes 
- 1 solution  for  warts 
One  significant  advantage  of the  Committee's  procedure  lies  in the 
l  .  f  h  l  l  .  .  (*)  l"  re  axat1on  o  t  e  anguage  ru es  set  out  1n  a  not1ce  to  app  1cants, 
which  is not  always  sufficiently known. 
It  should  be  remembered  on  the one  hand  that  the  largest  part of the 
dossier,  i.e. that  concerning  the  analytical, toxicological  and 
pharmacological  tests  and  clinical trials, is accepted  in  English 
by  all the  Member  States except  France,  and  in  French  by  all Member 
States except  Germany,  the  United  Kingdom  and  Ireland. 
The  "pharmaceuticals" dossier,  on  the other  hand,  which  concerns  the 
composition,  the  method  of preparation  and  the manufacturer's  routine 
checks,  is accepted  in  English  by  all the  Member  States except  France, 
Germany  and  Italy,  and  in  French  by  all the  Member  States except 
Denmark,  Germany,  Italy and  the  United  Kingdom. 
A conventional  order  of  presentation of the dossiers,  recommended  by 
the  Committee  for  Proprietary Medicinal  Products,  makes  the task of 
the  Committee  and  of the  manufacturers easier. 
.I. 
(*)  OJ  No  C 162,  2.7.1980 - 9  -
3.  Opinions  of  the  Committee 
The  case  provided  for  in  Article  10.1  of  Directive  75/319/EEC  where, 
in  the  absence  of  any  objections,  the  Committee  is not  required to 
give  its opinion,  has  not  so  far  arisen. 
Assessing  the benefits to  be  expected  from  a  therapeutic drug  as  against 
its actual  or  potential  risks  is a  difficult  and  complex  task  for  the 
national  authorities,  who  are  anxious  to elicit  as  many  guarantees  as 
possible  before  granting  marketing  authorization. 
3.1  ~~222o~9-2ei~£!i2o2 
The  frequency  of  the initial objections  raised  within the  120  days 
against  the  applications  indicates that  the  Member  States  have  so 
far  taken  a  very  cautious  approach.  The  national  authorities tend 
always  to  want  more  information than  is available  in  the dossier  which 
served  as  the  basis  for  the  authorization given by  the original 
Member  State  in  accordance  with  the  Directives. 
The  information  is often  already  in  the  possession of the  applicant 
but  he  has  not  seen  fit  to pass  it on  in  full. 
There  have  therefore  been  numerous  questions  regarding  the  analytical 
part  of  the dossier.  These  relate to: 
- the  impurities  resulting  from  the  method  of  synthesizing  the  active 
principle; 
-the exact  specifications of  starting materials  not  referred to  in 
the  European  or  relevant  national  Pharmacopoeia; 
- precise  nature  of  the  container; 
- checks  carried out  during  manufacture; 
- specificity of  the  method  of quantitative determination of the 
active  principle  in  the  finished  product; 
-details of  the  stability tests. 
Directives 75/318/EEC  and  75/319/EEC  require  the  submission  of  summaries 
and  an  expert  opinion  on  the  analytical,  pharmacological/toxicological 
and  clinical parts of  the dossier,  and  these  are  not  always  provided. 
Clear  presentation  and  clear  conclusions  would  undoubtedly  help  to 
reduce  the  number  of  these objections.  .1. - 10  -
Other  objections  are  of  a  more  serious nature,  calling  for  tests 
additional  to those  applied  for  the purpose  of the original  authorizat-
ion.  Some  of these tests,  such  as the  carcinogenicity test, might 
take  several  years to  complete.  A situation  Like  this  can  arise  when 
th~ original  authorization  was  granted  several  years previously but 
the opinion of the experts  has  since  moved  towards  tighter  requirements. 
Firms  are therefore  recommended  to  update  their dossiers  so  as  to 
adapt  them  to  the  scientific  requirements  prevailing  when  they  make 
their  new  application. 
In  a  few  cases difficulties  have  arisen owing  to the  small  therapeutic 
interest  of  products  which  do  not  Lend  themselves  to  controlled 
clinical testing.  It  would  seem  preferable to refrain  from  putting 
through  this procedure  products  which  have  only  marginal  indications 
and  the need  for  which  might  be  disputed. 
In  spite of  the  organizational  problems  encountered,  particularly as 
regards  the  rapid translation  and  dissemination of objections,  the 
Committee  has  always  managed  to deliver  its opinions  within the 
sixty days  allowed. 
The  21  opinions  rendered  by  the  Committee  up  to  September  1982  break 
down  as  follows: 
- 10  favourable  opinions, 8  of  which  were  unanimous; 
6  unfavourable opinions; 
- 5  divided opinions,  without  majority. 
In  view  of  the  frequency  of  the objections  received,  the  predominance 
of  favourable  opinions  illustrates the very  active part  played  by  the 
Committee,  which,  after discussion,  succeeds  in  removing  many  of the 
objections. 
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Even  in  its favourable  opinions  the  Committee  indicates to the 
manufacturer  those  points  in  the  dossier  which  still have  to  be 
clarified  in order  to  satisfy the  requirements  of the directives 
on  marketing  authorization.  Invariably,  the  need  is for  more  precise 
details  in  the  analytical  part  of  the dossier or  for  amendments  to 
the general  information or  the  package  insert. 
If a  favourable  opinion  is not  unanimous,  the  conflicting  views  are 
stated as  well. 
Unfavourable  opinions  adopted  by  the  Committee  as  a  whole  tend to 
call  into question  not  so  much  the products  themselves  as  substantial 
gaps  in  dossiers  which  have  been  submitted  without  having  been 
brought  up  to date. 
The  divided  opinions  and,  moreover,  the  conflicting  views  expressed 
in  some  of the  Committee's  favourable  opinions,  bear  witness to 
the multiplicity of  choice  in  public  health matters.  Any  medicinal 
product  has  its inherent  risks  and  there  is no  sure  criterion for 
fixing  the  level  of  risk  acceptable to each  Member  State  with  due 
regard to the therapeutic  advantage  hoped  for.  The  Commission,  for 
its part,  makes  sure  that  the opinions  expressed  keep  within the 
bounds  of  the  Treaty  and  the  Community  directives. 
3.3  ~£!i2D_!2-~~-!~~~0-20_!h~-fQ~~i!!~~~~-2eiOi2D§ 
When  favourable  opinions  contain  reservations,  marketing  authorizations 
cannot  as  a  rule  be  granted  within  the time  limit  of  30  days  from 
notification of the  Committee's  opinion. 
The  time  taken  by  manufacturers to  reply  to the questions  of the 
national  authorities on  the  grounds  of the op1nion  of the  Committee 
is itself very  variable  and  is  sometimes  beyond  the  Committee's 
control  if the  manufacturer  does  not  see  fit  to  send  it a  copy  of 
his  reply  to the  national  authorities  concerned. 
. I. - 12  -
As  a  remedy  for  these  drawbacks,  on  receipt  of  the  Committee's  opinion 
the  Member  States notify  it of  the  action they  intend to take.  The 
Committee  then  keeps  a  regular  check  on  the progress of applications 
which  are  pending,  until  the  final  decision  is taken  as to authoriz-
ation or  refusal. 
On  the  basis of  18  initial opinions  of the  Committee  - corresponding 
to 105  applications  for  marketing  authorization and  77  in principle 
favourable  positions of  individual  members  - 40  marketing  authorizations 
have  already  been  granted. 
In  the purely national  marketing  authorization procedure the  usual  time 
limits  for  examination  are  suspended  whenever,  as  is very  often the 
case,  the  authorities  want  additions  to the dossier  (Article 4(c)  of 
Directive  75/319/EEC).  In  ·like manner,  applications  which  have  been 
the  subject  of  an  opinion  from  the  Committee  receive the  same  treat-
ment  as  purely national  ones,  but  are  assured of direct  Community 
supervision of their progress. 
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III.  COOPERATION  WITHIN  THE  COMMITTEE 
1.  General 
The  Committee  for  Proprietary Medicinal  Products  meets  about  once 
every  two  months,  depending  on  the deadlines  resulting  from  the 
filing  of applications  for  marketing  authorization transmitted  by 
way  of  the  Committee's  procedure. 
Since  July  1981,  meetings  have  taken  place on  7  and  8  July,  6  and  7 
October  and  8  and  9  December  1981  and  on  6  and  7  April,  8  and  9  June 
and  7  and  8  September  1982. 
The  organization  and  work  of the  Committee's  secretariat  are  a  grow-
ing  burden  on  the  Commission.  To  give  an  example,  in  1981  the  Commit-
tee  for  Proprietary Medicinal  Products  alone  required the translation 
of  some  450  pages  of scientific texts. 
2.  Composition  of the  Committee 
The  term  of office of  the Chairman  and  the  members  is three years. 
The  Chairman  may  be  re-elected once  only. 
In  the  first  6  years  of the  Committee's  existence  Mr.  Leon  Robert 
took  the  Chair  for  two  terms,  having  previously taken part  as  the 
Luxembourg  representative  in  virtually all the initiatives and 
official  meetings  in  the field of  pharmaceuticals that  had  taken 
place  in  Europe  since  1947,  including  in particular the  European 
Pharmacopoeia,  the  Commission  of  which  he  had  chaired.  He  was 
supported  in  his  task  by  his  two  Deputy  Chairmen,  Professor  Duilio 
Poggiolini,  Director-General  of the  Italian Pharmaceutical  Service, 
and  Mr.  Nicolaas  Bel,  Head  of  the  Pharmaceuticals  and  Veterinary 
Medicinal  Products  Division of  the  Commission  of the  European 
Communities. 
At  the  meeting  of  September  1982  Dr.  Teijgeler,  President  of the 
College  ter  Beoordeling  van  Geneesmiddelen  in the  Netherlands, 
was  elected  Chairman  of  the  Committee  for  Proprietary Medicinal 
Products. 
.1. - ~  ,  ~  .... 
The  present  composition  of  the  Committee  is given  in  Annex 
3a  Exchange  of  information  within  the  Committee 
Since  1980  a  system  of  information  exchange  has  been  set  up  in  order 
to enable  the  Member  States the  better to  meet  their obligations 
under  Articles  30  and  33  of  Directive  75/319/EEC. 
A network  of national  correspondents  has  been  formed  and  is  constant-
Ly  updated  so  that  it  can  receive  by  telephone or  telex  information 
or  questions  on  medicinal  products,  especially  in  cases of emergency 
(Annex  Ill). Although  the network  is not  often  used  it was  considered 
very  important  to  keep  it in operation,  and  a  similar  system  was  ·set 
up  on  an  informal  basis  between  45  countries,  including  the  Member 
States of  the  Community,  at the  second  meeting  of  ICDRA  (the  Inter-
national  Conference  of  Drug  Regulatory  Authorities),  organized  by 
the  Italian Minister  of  Health  in  April  1982  under  the  patronage  of 
the  World  Health  Organization. 
Since  1980,  systematic  notifications to the  Committee  of  authorizat-
ions,  withdrawals,  refusals  and  suspensions  of medicinal  products 
have  numbered  about  5  500,  a  common  form  being  used  for  this purpose. 
The  Commission  has  redistributed  some  2  600  of these notifications 
to the  Member  States  for  information  and  to the  Council  of  Europe 
to  help  in  updating  Resolution  AP(77)1  on  medicinal  products  available 
only  on  prescription. 
After  the new  system  of  notifications  has  been  in operation  for  two 
years  the  Committee  plans  to establish  more  selective criteria for  the 
dissemination of  information  among  the  Member  States. 
.I  . 4.  Drug  monitoring 
At  each  of its meetings  the  Committee  discusses  questions  relating 
to the quality,  safety or  efficacy of particular  medicinal  products, 
as  required  by  Articles  12  and  14  of  Directive 75/319/EEC. 
The  discussion  mainly  concerns  the side effects of  certain 
medicaments:  information  available,  investigations  in  progress, 
conclusions of  scientific  symposia  or  procedures  for  hearing  the 
firms  concerned.  This  allows  the  national  authorities to  know  in 
advance  the  steps  which  the other  Member  States  intend to take. 
The  Members  of  the  Committee  have  made  it a  habit  to  consult  each 
other  before  taking  important  decisions  on  refusals,  withdrawals 
or  suspensions. 
Since  July  1981,  particular attention  has  been  paid to medicinal 
products  containing  the  following  active principles:  noramidopyrine, 
sodium  methanesulphonate,  phenazone,  propyphenazone,  emepronium 
bromide,  oxyphenisatine,  aristolochic  acid,  insoluble  salts of 
bismuth,  phenacetin,  progestagens,  benoxaprofene,  fenbufene,  tienilic 
acid,  penfluridol,  dexamethasone,  hydrocortisone,  association of 
chloramphenicol  with  tetracyclin, etretinate, bisoxatine,  ticlopidine, 
suxibuzone,  association of  benzylpenicillin  with  kanamycin,  tiaramide, 
feprazone,  gold salts,  ACTH,  nitrofurans,  anorexiants,  preparations 
based  on  Bac.  subt.,  benzyl  alcohol  for  preserving  injection 
solutions,  amphoprinol,  amrinone,  benfluorex. 
5.  Committee's  panels  of experts 
Under  Article  13  of  its rules  of  procedure,  the  Committee  has  so  far 
set  up  three  working  parties  as  and  when  the  need  has  arisen  • 
• 1. - 16  -
The  Working  Party  on  Medicinal  Products  of Plant  Origin,  chaired  by 
Professor  Schnieders,  has  not  met  again,  chiefly because of the 
differences of  ~pinion among  members  of the  Committee  as  to the tasks 
to  be  assigned to it. Professor  Schnieders  has,  however,  sent  the 
members  of the  Working  Party  a  good  deal  of documentation  resulting 
from  studies  carried out  by  an  ad  hoc  committee  of the  Bundes-
gesundheitsamt. 
The  Working  Party  on  the  Safety of  Drugs,  chaired by  Dr.  Griffin,  has 
held  no  further  meetings,  because  the  notes  for  guidance  which  it 
produced  to the  studies on  single-dose toxicity,  repeated-dose toxicity, 
reproduction,  carcinogenesis,  pharmacokinetics  and  metabolism  in 
animals  from  th~ safety  standpo1nt  are  annexed  to  a  proposal  for  a 
Recommendation(*)  that  is still being  discussed  in the  Council. 
The  working  paper  on  mutagen1city  (III/630/78  rev.  2)  will  be  brought 
up  to date  by  the  Working  Party  as  the  Council's discussions  progress. 
The  Working  Party  on  the  Efficacy of  Drugs,  chaired  by  Dr.  Dukes,  met 
on  12  and  13  October  1981  and  on  24  and  25  February  1982  and  made 
appreciable  progress towards  completing  twelve  notes  for  guidance 
which  are  in  various  stages  of  the process of written  consultation 
with  the national  authorities  and  the  pharmaceutical  industry,  as 
can  be  seen  in  Annex  IV.  The  Working  Party's programme  covered  a 
total  of  15  subjects,  the first  of  which,  namely  fixed  combination. 
products,  is  Likewise  annexed  to the  proposal  for  a  Council  Recommen-
.  (*)  L  l  .  "d  f  .  l  d  dat1on  ,  and  the  ast  two,  name  y  cort1co1  s  or top1ca  use  an 
antidysrhythmics,  have  made  very  Little progress.  Work  has  been  sus-
pended  for  the  time  being  since the departure of  Dr.  Dukes  for  the 
European  Regional  Office of the  WHO. 
A cons~ltation meeting  was  held on  6  September  1982  with  experts  from 
the pharmaceutical  industry  (European  Federation of  Pharmaceutical 
Industries'  Associations)  to deal  in particular with  the notes  for 
guidance  prepared by·the  Working  Party on  the Efficacy of  Drugs • 
• 1. 
<•>  OJ  'No  c 355, "31.12.80, ·pp  6-30 IV.  CONCLUSION 
The  Committee  for  Proprietary Medicinal  Products  has  helped  to insti-
tutionalize the  dialogue  between  the  representatives of the  Member 
States  who  are  responsible  for  the  marketing  of medicinal  products 
and  between  them  and  the departments of the  Commission. 
Although  Community  legislation on  medicinal  products  is for  the  most 
part  already  in existence,  the  individual  measures  taken  in this field 
by  each  of  the  Member  States  now  have  to  be  brought  into  line. 
In  this respect  the  Committee  is a  privileged  instrument  for  the 
harmonization  of national  policies with  regard to medicinal  products. 
Despite  the  fact  that  the  Committee's  role  is  limited to that  of  a 
consultative body  acting  on  behalf of the  Commission  and  the  Member 
States, the  importance  of its work  is now  internationally recognized, 
particularly since the two  international  confer.ences  of authorities 
responsible  for  medicinal  products  (I.C.D.R.A.)  that  were  held  under 
the  aegis of  the  World  Health  Organization  in  1980  and  1982. 
A working  Party on  the  Quality of  Drugs  may  be  set  up  in the  near 
future  to aid the  Committee  in its discussions  on  the  analytical 
part  of the dossiers  which  it is  called  upon  to examine. 
The  Commission  feels that  the  Committee  could play an  increasing part 
in  coordinating  the  review  of old medicinal  products,  the  registration 
dossiers  on  which  will  have  to be  brought  into  conformity  with  the 
Directives  by  1990. 
i 
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LIST  OF  ANNEXES 
Intra- and  extra-Community  trade  in  medicinal  products 
for  human  and  veterinary use,  Heading  No.  30.03 of the 
CCT 
Composition  of  the  Committee  for  Proprietary Medicinal 
Products 
List  of national  correspondents  for  the exchanges  of 
information  required  by  Directive  75/319/EEC 
Status of  work  of  the  Working  Party on  the  Efficacy of 
Drugs INTRA  AND  EXTRA  COMMUNITY  TRADE 
(Medicines  for  human  and  veterinary  use, 
Chapter  30.03 of the  Common  Customs  Tariff) 
1.  !~EQ~!§, in  millions  ECU,  C.C.T.  Chapter  30.03 
Import  year  EEC  D  F  IT  NL  B-L  UK  IRL 
1975  782  196  18  91  142  184  79  32 
% intra  EEC  74  %  67  %  83  %  72  %  87  %  79  %  59  %  90  % 
1976  1.034  258  21  117  199  230  107  42 
% intra  EEC  72  %  62  %  77  %  71  %  87  %  77  %  59  %  87  % 
1977  1.189  326  35  112  217  240  143  49 
% intra  EEC  73  %  63  %  87  %  73  %  84  %  76  %  65  %  97  % 
1978  1.447  410  55  143  259  277  168  59 
% intra  EEC  72  %  63  %  85  %  71  %  80  %  76  %  62  %  96  % 
1979  1.648  482  65  154  281  301  210  71 
% intra  EEC  72  %  65  %  78  %  72  %  80  %  76  %  65  %  98  % 
1980  1.849  540  101  182  296  322  231  87 
% intra  EEC  72  %  63  %  74  %  73  %  82  %  75  %  69  %  98  % 
1981  2.247  599  163  226  299  340  334  108 
% intra  EEC  70,5  %  60  %  77  %  71  %  82  %  68  %  68  %  98  % 
DK  GR 
40  -- 59  % 
56  -- 60  % 
67  -- 64  % 
77  -- 58  % 
82  -- 59  % 
90  -- 60  % 
101  78 
58  %  55  % 
2.  E~EQ~!§, in  millions  ECU,  c.c.T.  Chapter  30.03  (UK  1981  not  available) 
Export  year  EEC  D  F  IT  NL  B-L  UK  IRL  DK  GR 
1975  1.786  518  344  116  126  171  427  16  79  --
% intra  EEC  33  %  31  %  26  %  27  %  49  %  66  %  23  %  59  %  24  % 
1976  2.184  642  407  137  179  220  475  22  100  --
% intra  EEC  33  %  31  %  26  %  34  %  48  %  65  %  24  %  65  %  24  % 
1977  2.551  708  472  172  211  266  573  29  120  --
% intra  EEC  33  %  28  %  28  %  30  %  51  %  63  %  24  %  72  %  24  % 
1978  2.887  768  546  175  232  317  681  34  130  --
% intra  EEC  36  %  29  %  32  %  32  %  52  %  65  %  27  %  72  %  30  % 
1979  3.136  862  649  187  237  334  675  45  147  --
% intra  EEC  37  %  29  %  33  %  33  %  53  %  64  %  34  %  71  %  32  % 
1980  3.801  992  828  221  278  394  868  49  171  --
% intra  EEC  35  %  30  %  29  %  31  %  52  %  59  %  29  %  69  %  32  % 
1981  1.193  919  291  306  466  58  219  25  -- -- 30  %  31  %  26  %  53  %  58  %  67  %  33  %  6  %  % intra  EEC 
. 
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BIJLAGE  II  ANNEX  II 
octobre  I  October  1982 
COMPOSITION  DU  COMITE  DES  SPECIALITES  PHARMACEUTIQUES 
COMPOSITION  OF  THE  COMMITTEE  FOR  PROPRIETARY  MEDICINAL  PRODUCTS 
President  I  Chairman 
Dr.  C.A.  TEIJGELER,  Voorzitter  College ter  beo~rdeLing van  geneesmiddelen 
Vice-Presidents  I  Deputy  Chairmen 
- Prof.  Duilio  POGGIOLINI,  Direttore Generate del  Servizio  Farmaceutico 
Ministero della Sanita 
- M.  Nicolaas  BEL,  Chef  de  Division a La  Commission  des  Communautes 
europeennes  CD.G.  III/A-3> 
Secretariat du  Comite  des  specialites pharmaceutigues  I 
Secretariat of the  Committee  for  Proprietary Medicinal  Products 
D.G.  III A 3 
Commission  des  Communautes  europeennes 
Rue  de  La  Loi  200 
B-1049  Bruxelles 
Telephone 
Telex 
,-322 7  - 235.69.35 
- 235.51.80 
- 235.18.90 
21.877  COMEU  B 
•• • I ••• - 21  -
LISTE  DES  MEMBRES  I  LIST  OF  MEMBERS 
a)  Representants  I  Reer.esentatives 
b)  Suppleants  I  Deputies 
BELGIQUE 
a)  M.  Ben  HUYGHE 
b)  Mme.  Denise  TORFS-BRUDER 
DANMARK 
Inspecteur  General,  Inspection generate 
de  La  Pharmacie· 
Ministere  de  La  Sante  publique 
Cite  Administrative,  Quartier  Vesale 
1010  Bruxelles 
Tel.:  C2>  564.10.64 
Telex:  25.768 
Pharmacien-Inspecteur,  Chef  de  Service 
Inspection generale de  La  Pharmacie 
Ministere  de  La  sante  publique 
Cite  Administrative,  Quartier  Vesale 
1010  Bruxelles 
TeL.:  <2>  564.10.40,  564.10.41 
Telex:  25.768 
a)  Mr.  Hans  Otto  ANDERSEN  Sekretariatschef,. cand.  pharm. 
sundhedsstyrelsen,  Farmaceutiske  Laboratorium 
Frederikssundsvej  378 
DK-2700  Br!2)nsh!2)j 
T~l.: (2) 94.37. 73 
T~lex:  35333  IPHARM  OK 
b)  Mrs.  Agnete  Kj~rvig KRISTENSEN  Afdelingsleder  cand.  pharm. 
DEUTSCHLAND 
Sundhedsstyrelsen,  Farmaceutiske  Laboratorium 
Frederikssundsvej  378 
DK-2700  Br!2)nsh!2)j 
T~l.: (2) 94.37.73 
Telex:  35333  IPHARM  OK 
a)  Prof.  Dr.  Bernhard  SCHNIEDERS  Direktor  und  Professor 
Facharzt  fur  Pharmakologie 
b)  Prof.  Dr.  Jorg  SCHUSTER 
Leiter  des  Instituts fur  Arzneimittel 
des  Bundesgesundheitsamtes. 
Seestral1e  10 
D-1000  Berlin  65 
Tel.:  <3o>  45o.2o 
T  ~  leX :  183 31 0 
Direktor  und  Professor 
Facharzt  fur  Pharmakologie 
Zulassungskoordinator  im  Institut 
mittel  des  Bundesgesundheitsamtes 
Seestraf3e  10 
fur  Arznei-
D-1000  Berlin  65 
T~l.:  (30)  450.20  I  T~Lex:  183310  . I. FRANCE 
a)  M.  Pierre  GRECH 
b)  M.  le Professeur 
Jean-Michel  ALEXANDRE 
GREECE 
a>  Professor  U.  MARCELOU-KINTI 
(Mrs.> 
b)  Mrs.  G.  MELISSARATOU 
IRELAND 
a>  Dr.  Alene  SCOTT 
b>  Miss  M.C.  KLOOS 
- 22  -
Chef  de  service au  Ministere  de  la  Sante, 
Adjoint  au  Directeur de  La  Pharmacie  et 
du  Medicament 
Ministere  de  La  Sante 
Direction de  la  Pharmacie  et du  Medicament 
1,  place de  Fontenoy 
F-75700  Paris 
T~l.:  567.55.44,  poste  5492 
Ligne  directe  :  306.56.48 
T~lex  :  SANTSEC  2500  11  f 
Professeur  de  Pharmacologie  clinique au 
Centre  Hospitalier  universitaire 
BROUSSAIS 
96,  rue  Didot 
F-75014  Paris 
Tel.539.22.66,  poste  2349 
Vice-President  KEEF 
Vou lis  St r.  4 
Athens 
T~l.:  32.47.711 
Director 
Ministry  of  Social  Services 
Ari stote  l"ous  1t 
At hens 
Tel.:  coo301>  52.37.483 
Medical  Director 
National  Drugs  Advisory  Board 
Charles  Lucas  House 
63-64  Adelaide  Road 
Oubl in  2 
Tel.:  76.49.71  - 1 
Telex:  90542 
Pharmacist 
National  Drugs  Advisory  Bo•rd 
Charles  Lucas  House 
63-64  Adelaide  Road 
Dublin  2 
·'· IT ALIA 
a)  Prof.  Duilio  POGGIOLINI 
b)  Dott.  Romano  CAPASSO 
LUXEMBOURG 
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Direttore  Generale del  Servizio  Farmaceutico, 
Ministero della  Sanita 
Viale della  Civilta Romana,  7 
00144  ROMA,  EUR 
Tel.:  {6)  592.58.63  I  592.58.24 
Telex:  610453  MINSAN  I 
Consigliere  Ministeriale 
Ministero della  Sanita 
Direzione  Generate  Servizio  Farmaceutico 
Viale  della  Civilta Romana,  7 
00144  ROMA,  EUR 
TeL.:  <6)  593.58.28 
a)  Mme.  Josannette  LOUTSCH-WEYDERT  Pharmacien-Inspecteur 
Division de  La  Pharmacie  et  des 
Medicaments 
Boulevard  Joseph  II, 28 
Luxembourg 
TeL.:  C352>  47.55.01 
Telex:  2546  SANTE  LU 
b)  Mlle.  Mari~-Therese STROMMENGER  Pharmacien  attache  a  La  Division 
de  La  Pharmacie  et  des  Medicaments 
Boulevar9  Joseph  II, 28 
NEDERLAND 
a)  Dr.  L.  OFFERHAUS 
Luxembou-rg 
TeL.:  <352>  47.55.01 
Internist 
Hoofd  van  de  Afdeling  Farmacotherapie 
van  het  Staatstoezicht op  de  Volks-
gezondheid  van  het 
Ministerie  van  Volksgezondheid  en 
·Mil ieuhygi ene 
Plaatsvervangend  Voorzitter  van  het 
College  ter beoordeling  van  geneesmiddelen 
Postbus  5811 
2280  HV  RIJSWIJK 
Tel.:  <70)  94.95.05,  ext.  228 
. I. UNITED  KINGDOM 
a)  Dr.  J.P.  GRIFFIN 
b)  Dr.  G.  JONES 
CCE  I  CEC 
a)  M.  Nicolaas  BEL 
b)  M.  Fernand  SAUER 
- 24  -
Senior  Principal  Medical  Officer 
Department  of  Health  and  Social  Security 
Medicines  Division 
Market  Towers 
1  Nine  Elms  Lane 
London  SW8  SNQ 
TeL.:  <1>  720.21.88 
Telex:  883669 
Principal  Medical  Officer 
Department  of  Health  and  Social  Security 
Market  Towers 
1  Nine  Elms·  Lane 
London  SW8  SNQ 
Tel.:  C1>  720.21.88 
Chef  de  La  Division 
11Pharmacie,  medicaments  veterinaires" 
Commission  des  Communautes  europeennes 
D.G.  IIIIA-3 
Tel.:  <2>  2351891 
Telex:  21877  COMEU  B 
Administrateur 
Commission  des  Communautes  europeennes 
O.G.  IIIIA-3 
Tel.:  (2)  2355180  I  2356935 ANNEXE  III 
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COMMISSION  octobre  I  October  1982 
DES 
COMMUNAUTES  EUROPEENNES 
Direction generale du 
marche  interieur et  des 
affaires industrielles 
ECHANGE  D'INFORMATIONS  l 
EXCHANGE  OF  INFORMATION  Directive  75/319/CEE  EEC 
COMITE  DES  SPECIALITES  PHARMACEUTIQUES 
COMMITTEE  FOR  PROPRIETARY  MEDICINAL  PRODUCTS - 26  -
ETAT  MEMBRE 
MEMBER  STATE  BELGIQUE 
PERSONNES  RESPONSABLES  DE  L1INFORMATION  }  CEE  Directive 75/319/  PERSONS  RESPONSIBLE  FOR  INFORMATION  EEC 
Nom  et  Fonction  Adresse  Type  d' i nfor- I 
Name  and  Function  Address  Teleph.  &  Telex  mation  (*) 
Type  of 
information  (*) 
Mr.  VAN  HERPE,  G.  Ministere  de  La  (2)564.10.29  ( 1) 
ConseiLler  Sante  publique et  (2)564.10.64  (2) 
de  La  Fami LLe  (3) 
Inspection general  ~  Telex:  25768 
de  La  Pharmacie 
Rue  Montagne  de 
l'Oratoire,  10 
B-1010  BruxeLles 
Mad.  ROLAND,  N.  - II  - (2)564.10.48  (4) 
Inspecteur  564.11.48 
Mad.  THYS,  I.  - '' - (2)564.10.46  (4) 
Pharmacien 





I  - . 
(*)  1.)  autorisations  de  mise  sur  Le  marche  I  marketing  authorizations 
2.)  retrait  de  lot,  interdiction de  deLivrance  I  batch  withdrawal, 
prohibition of  supply 
3.)  autorisation de  fabrication,  inspections  I  manufacturing  aut h  or  i z at  i on, 
inspection 
4.)  pharmacovigilance  I  drug  monitoring ETAT  MEMBRE 
MEMBER  STATE 
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PERSONNES  RESPONSABLES  DE  L'INFORMATION  ~ 
PERSONS  RESPONSIBLE  FOR  INFORMATION  1 
D E N M A R K 
Directive 75/319/CEE 
EEC 
Nom  et  Fonction  Adresse  Teleph.  &  Telex  Type  d'infor-
Name  and  Function  Address  mation  (*) 
Type  of 
information 
Mr.  H.O.  Andersen  Sundhedsstyrelsen  (02)  94.37.73  ( 1) 
Sekretariatschef  Frederikssunds- (2) 
~ej  378,  Telex:  35333 
~K-2700 Br¢nsh¢j  ipharm  (4) 
Mrs.  Agnete  Kj~rvig  - II  - (02)  94.37.73  (1) 
Afdelingsleder  Telex:  35333  (2) 
ip~arm 
Bodil  Str¢h  National  Board  of  (01)  14.10.11  (2) 
Head  of  Medicines  Health 
Supply  Section  St.  Kongensgade  1  (3) 
DK-1264  K¢benhavn  ~ 
Jens  Over¢  Danmark 
Head  of  Medicines 
Division  - "  -
(*)  1.)  autot·i:;;a~ions  c;2  mise  sur  le  marche  I  m;:r·!o:-ting  aL•thoriza+ions 
2.)  n.~triJit  de  lot.,  )nterdiction de  delivrance  I  batch  ~:!ithdr;l'·•al,., 











3.1  autor  ·i~di. iu11  de  i.:Jbrica~·ion,.  insi-Jt:ction~:.  '  j;;,;Hlu'fat.L~Jfing  ·~~~:~~K''·izati0n,. 
inspection 
4.)  pharmacovigilance  I  drug  monitoring ETAT  MEMBRE 
MEMBER  STATE 
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BUNDESREPUBLIK  DEUTSCHLAND 
PERSONNES  RESPONSABLES  DE  L'INFORMATION  ~ 
PERSONS  RESPONSIBLE  FOR  INFORMATION  j  Directive 75/3191CEE  EEC 
Nom  et  Fonction 
Name.and  Function 
Adresse 
Address  Teleph.  &  Telex  Type  d'infor- I 
mation  <•> 
Type  of 
information  <•> 
~------------------~--------------~--------------+-----------~Teleph  privat.  Dir.  u.  Prof. 
Dr.  B.  Schnieders 
Head  of  Institute 
Dir.  u.  Prof. 
Dr.  J.  Schuster 
Coordination of 
registration of  drugs 
Dir.  u.  Prof. 
Dr.  G.  Stille 
Head,  Department 
experim./clinical 
pharmacology 
Dir.  u.  Prof. 
Dr.  P.  Schonhofer 
Head,  Department 
Drug  monitoring 
Institut  fur  Arz- (30)  450.20 
neimittel  des 
Bundesgesundheits- Telex:  183310 
amtes 
SeestraOe  10 
D-1000  BERLIN  65 
- II  - - II  ._ 
- II  - - II  -
- II  - - .,  -
1, 2,  4 
1 
1 
2,  4 
Dr.  K.  Feiden  ~undesministerium fur  (228)  338  251  3  1  Ministerialrat  ~ugend,  Familie  und  1 
~esundheit,  I 
Dr.  Chr.  Gaudich  ·postf.  200490  (228)  338  335  3  , 
Regierungsdirektorin  5  0  Telex:  8-85  517  I 
------------~~D-..=:...:::3:.!:::0~8~o~n~n~2---'----------+----------·. 
(*)  1.)  autorisations de  mise  sur  Le  marche  I  marketing  authorizations 
2.)  retrait  de  lot,  interdiction de  delivrance  I  batch  withdrawal, 
prohibition of  supply 
8117829 
3.)  autorisation de  fabrication,  inspections  I  manufacturing  authorization, 
inspection 
4.)  pharmacovigilance  I  drug  monitoring ETAT  MEMBRE 
MEMBER  STATE 
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PERSONNES  RESPONSABLES  DE  L'INFORMATION  ~ 
PERSONS  RESPONSIBLE  FOR  INFORMATION  j 
F R A N C E 
Directive 75/319/CEE 
EEC 
Nom  et  Fonction  Adresse  Teleph.  &  Telex  Type  d' i nfor-
Name  and  Function  Address  mation  (*) 
Type  of 
information  (*) 
Pierre  GRECH  Ministere  de  La  567.55.44  1,  2,  3,  4 
Chef  de  Service  sante  Peste  54.92 
Adjoint  au  Directeur  Direction de  La 
Pharmacie  et  du  Ligne  directe: 
Medicament  306.59.48 
1, place  de 
Fontenoy 
F-75700  PARIS 
Yvonne  CHAVAUDRET  - " - 567.55.44  1,  2,  3,  4 
Pharmacien  Peste  55.04 
charge  du  bureau 
des  Affaires  Ligne  directe: 











I  -·. 
(*)  1.)  autorisations  de  mise  sur  le marche  I  marketing  authorizations 
2.)  retrait de  lot,  interdiction de  delivrance  I  batch  withdrawal, 
prohibition of supply 
1 
3.)  autorisation de  fabrication,  inspections  I  manufacturing  authorization, 
inspection 
4.)  pharmacovigilance  I  drug  monitoring ETAT  MEMBRE 
MEMBER  STATE 
- 30  -
G R E C E 
PERSONNES  RESPONSABLES  DE  L'INFORMATION  ~ 
PERSONS  RESPONSIBLE  FOR  INFORMATION  j  Directive 7513191CEE 
EEC 
Nom  et  Fonction 
Name  and  Function 
Adresse 
Address 
Prof.  U.  Marcelou-Kinti  K E E  F 
Vice-President  (Mrs.)  Voulis  St.  4 
of  KEEF  Athens  125 
Mrs.  G.  Melissaratou 
Pharmacien 
Director 
Mrs.  E.  Vardacosta 
Head,  Directorate of 
pharmaceuticals  and 
pharmacies 
Ministry  of 
SociaL  Services 
Aristotelous  17 
Athens 
Ministry  of  Social 
Services 
Aristotelous  17 
Athens 
State  Laboratory  Miss  A.  Varveri 
Head,  Section of 
and  Proposals 
(EEC,  FDA,  WHO) 
Studies  for  the  control 
of  pharmaceuticals 
Voulis  St.  4 
Athens  125 














Type  d' i nfor- -, 
mation  (*) 
Type  of 
information  (*) 
1,  2,  4 
3 
1,  2 
3, 4 
'------------1---------...l-------__....J"-----------·' 
(*)  1.)  autorisations  de  mise  sur  le  marche  I  marketing  authorizations 
2.)  retrait de  lot,  interdiction de  delivrance  I  batch  withdrawal, 
prohibition of  supply 
3.)  autorisation de  fabrication,  inspections  I  manufacturing  authorization, 
inspection 
4.)  pharmacovigilance  I  drug  monitoring - 31  -
ETAT  MEMBRE 
MEMBER  STATE  IRELAND 
PERSONNES  RESPONSABLES  DE  L'INFORMATION  ~  Directive 7513191 CEE 
PERSONS  RESPONSIBLE  FOR  INFORMATION  j  EEC 
Nom  et  Fonction  Adresse  Teleph.  & Telex  Type  d' i nfor-
Name  and  Function  Address  mation  (*) 
Type  of 
information  (*) 
Dr.  A.  SCOTT  NationaL  Drugs  76.49.71 .- 7  1, 2,  3,  4 
Medical  Director  Advisory  Board 
Charles  Lucas  House 
63-64  Adelaide  Road 







I  ---. 
'*' 
1 • )  autorisations  de  mise  sur  le marche  I  marketing  authorizations 
2.)  retrait  de  lot,  interdiction de  delivrance  I  batch  withdrawal, 
prohibition of  supply 
t 
3.)  autorisation de  fabrication,  inspections  I  manufacturing  authorization, 
inspection 
4.)  pharmacovigilance  I  drug  monitoring - 32  -
ETAT  MEMBRE  I  T A L I  A 
MEMBER  STATE 
PERSONNES  RESPONSABLES  DE  L
1INFORMATION  ~  Directive 7513191 CEE 
PERSONS  RESPONSIBLE  FOR  INFORMATION  1  EEC 
Nom  et  Fonction  Adresse  Teleph.  &  Telex  Type  d'infor-
Name  and  Function  Address  mation  (*) 
Type  of 
information  (*) 
Prof.  Duilio  POGGIOLINI  Ministero  della  (6)  592.58.63  1,  2,  3,  4 
Direttore  Generale  del  Sani t a  (6)  592.58.24 
Servizio  Farmaceutico  Servizio 
Farmaceutico  Telex: 
Viale  della  610453  MINSAN  I 
Civilta  Romana,  7 
00144  ROMA  EUR 
Dr.  Romano  CAPASSO  - "  - ( 6)  592.58.28  1, 2, 3,  4 








(*)  1 • )  autorisations  de  mise  sur  le marche  I  marketing  authorizations 
2.)  retrait  de  lot,  interdiction de  delivrance  I  batch withdrawal, 
prohibition of supply 
I 
3.)  autorisation de  fabrication,  inspections  I  manufacturing  authorization, 
inspection 
4.)  pharmacovigilance  I  drug  monitoring ETAT  MEMBRE 
MEMBER  STATE 
- 33  -
PERSONNES  RESPONSABLES  DE  L1INFORMATION  ~ 




Nom  et  Fonction  Adresse  Teleph.  &  Telex  Type  d' i nfor-
Name  and  Function  Address  mation  (*) 
Type  of 
information 
Mad.  LOUTSCH-WEYDERT,  "'·  Division  de  La  47.55.01  1, 2,  3,  4 
Pharmacie  et  des 
Medicaments  Telex: 
28,  bd.  Joseph  II 
Luxembourg  2546  SANTE  LU 
(*)  1.)  autorisations  de  mise  sur  le marche  I  marketing  authorizations 
2.)  retrait  de  lot,  interdiction de  delivrance  I  batch  withdrawal, 









3.)  autorisation de  fabrication,  inspections  I  manufacturing  authorization, 
inspection 
4.)  pharmacovigilance  I  drug  monitoring ETAT  MEMBRE 
MEMBER  STATE 
- 34  -
PERSONNES  RESPONSABLES  DE  L'INFORMATION  ~ 




Nom  et  Fonction 
Name  and  Function 
Adresse 
Address  Teleph.  &  Telex  Type  d'infor- 1 
mation  (*) 
Drs.  R.A.  ~rost,  Ministerie  van 
inspecteur  Volksgezondheid, 
College  ter beoor-
deling  van 
geneesmiddelen 
Case  postale  5811 
2280  HV  Rijswijk  (ZH) 
Dr.  C.A.  Teijgeler,  Ministerie  van 
Voorzitter  Volksgezondheid, 
College  ter 
beoordeling  van 
geneesmiddelen 
Case  postale  439 
2260  AK  Leidschendar 
Drs.  R.H.B.  Meyboom, 
inspecteur  - II  -
(70)  94.95.05 
Telex:  32691  --
(70)  20.92.60 
Telex:  32362 
v  m nl 
- II  -
Type  of 
information  (*) 
1 
2  +  3 
4 
~--------------------~----------------~------------~~-------------
(*)  1.)  autorisations  de  mise  sur  le marche  I  marketing  authorizations 
2.)  retrait  de  lot,  interdiction de  delivrance  I  batch  withdrawal, 







3.)  autorisation de  fabrication,  inspections  I  manufacturing  authorization, 
inspection 
4.)  pharmacovigilance  I  drug  monitoring ETAT  MEMBRE 
MEMBER  STATE 
- 35  -
PERSONNES  RESPONSABLES  DE  L1INFORMATION  ~ 
PERSONS  RESPONSIBLE  FOR  INFORMATION  ; 
UNITED  KINGDOM 
Directive  7513191CEE 
EEC 
Nom  et  Fonction  Adresse  Teleph.  &  Telex  Type  d' i nfor-
Name  and  Function  Address  mation  (*) 
Type  of 




(1)  720.21.88 
Mr.  w.  CROSTON  DHSS  ext.  3413  1 
Principal  Licensing  Market  Towers 
Officer  1  Nine  Elms  Lane 
London  SW8  5NQ 
Mr.  R.  BAKER  - II  - ext.  3353  or  2  +  3 
Superintending  3354 
Medicines  Inspector 
Dr.  R.  PENN  - II  - ext.  3143  or  4 
Principal  Medical  3146 
Officer 
(*)  1.)  autorisations  de  mise  sur  le  marche  I  marketing  authorizations 
2.)  retrait  de  lot,  interdiction de  dtH i vrance  I  batch withdrawal, 








3.)  autorisation de  fabrication,  inspections  I  manufacturing  authorization, 
inspection 
4.)  pharmacovigilance  I  drug  monitoring • 
- 36  -
COMMISSION  DES  C.E.  . I 
COMMISSION  OF  THE  E.C,  _ 
PERSONNES  RESPONSABLES  DE  L'INFORMATION  ~  Directive 7513191 CEE 
PERSONS.RESPONSIBLE  FOR  INFORMATION  j  EEC 
Nom  et  Fonction  Adresse  Type  d' i nfor- l 
Teleph.  &  Telex  Name  and  Function  Address  mation  <•> 
Type  of 
information 
Mr.  N.  BEL  Commission  des  (2)  235.18.91  ou  1, 2,  3, 4 
Chef  de  Division  Communautes  (2)  235.18.90 
europeennes  <secretariat> 
D.G.  III/A-3  ou 
Rue  de  La  Loi  200  (2)  235.69.35 
B-1049  Bruxelles  <secretariat> 
Telex: 
21877  COMEU  B 
Mr.  F.  SAUER 
1, 2,  3,  4  Administrateur  - " -
_  II  -
(2)  235.51.80 ou 
(2)  235.69.35 
<secretariat> 
., 
<*>  1.>  autorisations de  mise  sur  le marche  I  marketing  authorizations 
2.)  retrait de  lot,  interdiction de  delivrance  /·batch withdrawal, 






I  -·. 
3.)  autorisation de  fabrication,  inspections  I  manufacturing  authorization, 
inspection 
4.)  pharmacovigilance  I  drug  monitoring ANNEXE  IV  ANLAGE  IV  ALLEGATO  IV  BIJLAGE  IV  ANNEX  IV 
OAP.l\PTHMA  JV 
COMMITTEE  FOR  PROPRIETARY  MEDICINAL  PRODUCTS 
PROGRESS  REPORT  ON  EFFICACY  GUIDELINES 
Stages:  1  2  3  4  5·  6  7  81'· 
Fixed  combinations  III/115/79  01-78 .....  ••  e  a  a  I .  .... .  .... 11-78 
Cardiac glycosides  III/635/78  11-78  12-78 ...... .  .  .  .  . 06-80  11-80 
Or.contr.clinical  III/571/79  03-79  06-79  02-80  05-80  06-80  11-80 
Or.contr.inform.  III/572/79  03-79  06-79  02-80  05-80  06-80  11-80 
Antihypertensive  III/1667/79 05-80  05-80 ..... .  .  .  .  . .  .... .  .... 
Long-term  use  III/602/81  12-81  01-82 
N.St.Anti-Inflam.  III/601/81  01-78  ..... 10-81  12-81  01-82 
Antiepileptic  III/634/78  04-78  06-78  10-81  12-81  01-82 
Bioavailability  III/573/79  03-79  06-79  10-81  12-81  01-82 
Pharmacokin.in  man  III/603/81  12-81  01-82 
Anti anginal  III/1261/78  11-78  12-78  02-82 
Ischaemia  in the.  III/1270/81  12-81  01-82 
.  .  b'  llimbs  Ant1m1cro  1a  III/1666/79  05-80  05-80  02-82 
Topical  corticoids  III/225/82 
Anti dysrhytmi c 
1. = Subject  of  instruction t9 the working  party 
2.  =Reference No.  of draft  actively prepared.by working  party 
3.  =  Draft  submitted to  CPMP 
BILAG  IV 
March  1982 
9 
O.J.E.C.31-12-80  C355 
(OMS/WHO  text> 
4. = Draft  forwarded  to national  agencies  and  industry  for  first  comments 
5.  =  Rediscussion of  comments  in the .working  party 
6.  =  Revised  version before  CPMP 
7. = Draft  circulated to national  agencies  and  industry 
8.  =  Approval  by  CPMP 
9.  =  Adoption  and  publication 
II  • 